10 Stocks That Will Go To The Moon in 2026

Page 1 of 9

In this article, we will look at the 10 Stocks That Will Go To The Moon in 2026.

2026 is said to be an inflection point in the AI trade. To discuss this, Dan Ives, Wedbush Securities, joined CNBC television on December 20. He noted that analysts like himself believe 2026 to be an inflection point mainly due to the monetization of the AI revolution, particularly on the software side. Ives highlighted that the use cases of AI have now started to present themselves in software offerings and agentic products.

Ives had released a note earlier, highlighting that tech stocks can be up over 20% in 2026. He elaborated that he expects large-cap tech stocks, specifically the Mag Seven, to be up more than 20%. He highlighted that stocks like Microsoft and Google can be up 30% to 40%. Ives elaborated that there’s more than $3 trillion to $4 trillion, which will be spent in the next 3 to 4 years, and this is just the start of the next phase in the AI trade. He noted that now the tech companies are entering cross-infrastructure and cross-cybersecurity deals, thereby further improving the case for AI. Ives sees the sell-off in some of the big names as a perfect buying opportunity.

With that, let’s take a look at the 10 Stocks That Will Go To The Moon in 2026.

10 Stocks That Will Go To The Moon in 2026

Our Methodology

To curate the list of 10 Stocks That Will Go To The Moon in 2026, we used the Finviz stock screener, CNN, and Insider Monkey’s Q3 2025 hedge fund database. Using the screener, we aggregated a list of stocks for which analysts see more than 50% upside. Next, we cross-checked the upside potential from CNN and ranked the stocks in ascending order of the number of hedge fund holders sourced from Insider Monkey’s database. Please note that the data was recorded on December 19, 2025.

​Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 427.7% since May 2014, beating its benchmark by 264 percentage points (see more details here).

10 Stocks That Will Go To The Moon in 2026

10. BioNTech SE (NASDAQ:BNTX)

Analyst Upside Potential: 53.64%

Number of Hedge Fund Holders: 24

BioNTech SE (NASDAQ:BNTX) is one of the Stocks That Will Go To The Moon in 2026. On December 18, BioNTech SE (NASDAQ:BNTX) announced the closing of its acquisition of CureVac N.V. (NASDAQ:CVAC), which is another mRNA-focused biotech firm from Mainz, Germany.

Management noted that the deal had closed after the expiration of the subsequent offering period in exchange for CureVac’s shares. As a result, the company now holds a majority stake in CureVac. This enables the company to integrate CureVac’s pipeline for oncology and infectious diseases.

In another update, on December 11, H.C. Wainwright reiterated a Buy rating on BioNTech SE (NASDAQ:BNTX) with a $140 price target.

The bullish sentiment is based on the interim data from a Phase 2 trial testing Pumitamig (BNT327/BMS-986545), which is a bispecific antibody that targets both PD-L1 and VEGF-A. The treatment is being tested for patients with triple-negative breast cancer (TNBC). The results showed strong anti-tumor activity and tolerable safety. Management noted that the results support advancing to a Phase 3 trial called ROSETTA-BREAST-01.

H.C. Wainwright noted that the trial showed an impressive 72% overall response rate along with 62% confirmed ORR in first-line and second-line TNBC patients. The firm added that these impressive results derisk the ongoing phase 3 trials, suggesting the strong potential of Pumitamig plus chemotherapy becoming a treatment for first-line TNBC patients with PD-L1 expression.

BioNTech SE (NASDAQ:BNTX) is a German biotechnology company that develops and commercializes novel immunotherapies and vaccines for cancer and infectious diseases. It is widely recognized for creating the first approved mRNA-based drug, the Pfizer-BioNTech COVID-19 vaccine, sold under the brand name Comirnaty.

9. IonQ, Inc. (NYSE:IONQ)

Analyst Upside Potential: 50.58%

Number of Hedge Fund Holders: 30

IonQ, Inc. (NYSE:IONQ) is one of the Stocks That Will Go To The Moon in 2026. On December 17, IonQ, Inc. (NYSE:IONQ) announced expanding its agreement with QuantumBasel. The extension in the contract allows QuantumBasel to extend ownership of the company’s Forte Enterprise system and a next-generation Tempo system.

Management noted that as a result of this contract extension, the total value of the contract between the two entities is over $60 million. Moreover, this also allows the company to stay in Switzerland for four more years. QuantumBasel acts as IonQ, Inc.’s (NYSE:IONQ) official European Innovation Center, giving companies, universities, and researchers hands-on access to the company’s advanced quantum hardware. The expansion includes new joint research on optimizing large language models and hybrid quantum-classical methods.

That said, on December 17, Antonie Legault from Wedbush initiated coverage of IonQ, Inc. (NYSE:IONQ) with a Buy rating and a $60 price target. Earlier on December 16, Richard Shannon from Craig-Hallum also reiterated a Buy rating on the stock without disclosing any price targets.

Legault from Wedbush noted that the company’s 25 years of research have emerged in a unique and powerful architecture. The firm highlighted that although the technology is new and the adoption remains limited, the company has developed a strong sales pipeline. The firm highlighted that the sales of IonQ, Inc. (NYSE:IONQ) have nearly doubled from 2023 to 2024, and 2025 is expected to see sales doubling again.

IonQ Inc. (NYSE:IONQ) develops quantum computers and networks in the US.

Page 1 of 9